Agios Pharmaceuticals Inc. (NASDAQ:AGIO) insider Scott Biller sold 5,000 shares of the stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $55.00, for a total transaction of $275,000.00. Following the sale, the insider now directly owns 48,270 shares of the company’s stock, valued at approximately $2,654,850. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Scott Biller also recently made the following trade(s):
- On Tuesday, September 20th, Scott Biller sold 5,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00.
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) opened at 53.26 on Wednesday. Agios Pharmaceuticals Inc. has a 52 week low of $33.50 and a 52 week high of $81.77. The company’s market capitalization is $2.03 billion. The firm’s 50-day moving average price is $46.87 and its 200 day moving average price is $46.58.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.99. Agios Pharmaceuticals had a negative net margin of 320.33% and a negative return on equity of 47.69%. The company earned $6.98 million during the quarter, compared to the consensus estimate of $39.62 million. During the same quarter in the previous year, the firm posted ($0.85) EPS. The business’s revenue for the quarter was down 47.2% compared to the same quarter last year. Equities research analysts expect that Agios Pharmaceuticals Inc. will post ($5.04) earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in the stock. Opaleye Management Inc. acquired a new position in Agios Pharmaceuticals during the first quarter valued at about $4,263,000. Royal Bank of Canada boosted its position in Agios Pharmaceuticals by 65.0% in the first quarter. Royal Bank of Canada now owns 4,465 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 1,759 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in Agios Pharmaceuticals during the first quarter valued at about $318,000. Bellevue Group AG acquired a new position in Agios Pharmaceuticals during the first quarter valued at about $2,192,000. Finally, A.R.T. Advisors LLC acquired a new position in Agios Pharmaceuticals during the first quarter valued at about $1,185,000. Hedge funds and other institutional investors own 81.59% of the company’s stock.
A number of analysts have weighed in on AGIO shares. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, July 12th. Goldman Sachs Group Inc. reaffirmed a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, August 10th. BTIG Research initiated coverage on shares of Agios Pharmaceuticals in a research report on Friday, August 19th. They set a “neutral” rating for the company. Canaccord Genuity reaffirmed a “buy” rating and set a $90.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, September 8th. Finally, Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $63.44.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.